BioStem Technologies, Inc.
BSEM - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$20.91M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $20.91 Million |
|---|---|
| Enterprise Value | $15.17 Million |
| Earnings per Share | $-0.39 |
| Beta | 0.27 |
| Outstanding Shares | 17,327,652 |
Return
| Return on Equity | -102.45% |
|---|---|
| Return on Assets | -57.95% |
| Return on Invested Capital | -84.50% |
Valuation & Multiples
| P/E Ratio | -0.67 |
|---|---|
| PEG | -0.05 |
| Price to Sales | -0.28 |
| Price to Book Ratio | 1.12 |
| Enterprise Value to Revenue | -0.25 |
| Enterprise Value to EBIT | -0.65 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.50
Consensus analyst estimateRevenue Estimate
$6.35 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-0.43
Consensus analyst estimateRevenue Estimate
$7.17 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About BioStem Technologies, Inc.
73 employees
CEO: Jason Matuszewski
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue a...